Navigation Links
Using Growth Hormone for Boosting Performances is Hazardous

A 36-year-old professional body-builder who used growth hormone to boost his performance landed up with inflamed liver and enlarged// kidneys according to a report.

He was admitted with chest pain for emergency treatment. He had lost 40 kg in 12 months, during which he had also experienced excessive urination, thirst, and appetite.

He admitted using anabolic steroids for 15 years and artificial growth hormone for the past three. He had also taken insulin, a year after starting on the growth hormone.

This was done to counter the effects of high blood sugar, but he had stopped taking it after a couple of episodes of acute low blood sugar (hypoglycaemia) while at the gym.

Tests revealed that his liver was inflamed, his kidneys were enlarged and that he had very high blood sugar. He was also dehydrated, and diagnosed with diabetes.

He was given intravenous fluids and gradually increasing amounts of insulin over five days, after which he was discharged. His symptoms completely cleared up, and he was no longer diabetic.

The use of growth hormone has steadily risen among amateur athletes and bodybuilders all round the world, say the authors, because it is easy to buy online and difficult to detect in screening tests—unlike anabolic steroids.

The authors believe that this is the first reported case of diabetes associated with the use of high dose growth hormone, and urge anyone taking high doses to regularly check their blood sugar levels.

Source-Eurekalert
PRI
'"/>




Page: 1

Related medicine news :

1. Preventing Strokes Using Less Invasive Techniques
2. Using Cholesterol Lowering Drugs Effectively
3. Using herbal remedies with chemotherapy may not be a good idea
4. Teenagers Using Hormones And Dietary Supplements To Good Physique
5. Using Stem Cells To Treat Incontinence In Women
6. Using Eyes As The Line Of Reference For Fetal Brain Imaging
7. Remote Robotic Surgery Using Miniature Robots
8. Driving While Using A Mobile Phone May Be Dangerous
9. Detecting Brain Abnormalities in Babies Using New Brain Scanners.
10. Mobilizing Stem Cells at the Injured Site Using Hyperbaric Oxygen Treatments.
11. Treatment of Sickle Cell Anemia Using Gene Therapy.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: